@article{ATM8238,
author = {Jun Guo and Jianhui Ma and Yan Sun and Shukui Qin and Dingwei Ye and Jianfang Zhou and Zhisong He and Xinan Cheng and Feng Bi and Dengfeng Cao and Yingxia Chen and Yiran Huang and Houjie Liang and Jun Liang and Jiwei Liu and Wenchao Liu and Yueyin Pan and Yongqian Shu and Jian Song and Weibo Wang and Xiuwen Wang and Xiaoan Wu and Xiaodong Xie and Xin Yao and Shiying Yu and Yanqiao Zhang and Aiping Zhou and written on behalf of CSCO Renal Cell Carcinoma Panel},
title = {Chinese guidelines on the management of renal cell carcinoma (2015 edition)},
journal = {Annals of Translational Medicine},
volume = {3},
number = {19},
year = {2015},
keywords = {},
abstract = {The guideline was established by the kidney cancer panel under the Chinese Society of Clinical Oncology (CSCO) in accordance with the basic principles of evidence-based medicine (Table 1) and the clinical practices on renal cancer in China, based on the real conditions of China, and by referring to the USA NCCN Clinical Practice Guidelines in Oncology-Kidney Cancer (1) and the European Association of Urology (EAU) Guidelines on Renal Cell Carcinoma (2). The renal cancer referred in these guidelines is the renal cell carcinoma (RCC) and does not include various tumors originated from renal interstitium and renal pelvis/urothelial system.},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/8238}
}